| MEIRAGTX HLDGSDL-,0000388 |
| China |
| Gesundheit |
| KYG596651029 / A2JGHF |
| 328 (Frankfurt) / MGTX (NASDAQ) |
| FRA:328, ETR:328, 328:GR, NASDAQ:MGTX |
| - |
| https://meiragtx.com/ |
|
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing novel treatments for serious diseases. The company's primary aim is to harness the transformative potential of gene therapy to address otherwise unmet medical needs...
>Volltext.. |
| 664.93 Mio. EUR |
| 684.24 Mio. EUR |
| 69 Mio. EUR |
| -80.39 Mio. EUR |
| -96.82 Mio. EUR |
| -1.21 EUR |
| 75.19 Mio. EUR |
| 55.89 Mio. EUR |
| -39.3 Mio. EUR |
| 0.54 |
| 115.57% |
| 31.89% |
| - |
| - |
| - |
| MEIRAGTX |
| 15.04.26 |
|